RESEARCH LIBRARY / 2026Semax. Selank. Bromantane. Oral BPC-157. Explore the research behind the names—and learn which questions the evidence can actually answer.
With optional research emails. Eligibility and checkout terms apply.
Focus, anxiety, and the gut–brain question.
Compare four compounds without losing the study context. Focus is a popular headline. It is also an imprecise research endpoint. Attention, memory, anxiety, fatigue, and neurological recovery are different questions. This playbook gives you a map of Semax, Selank, bromantane, and oral BPC-157, with a practical framework for evaluating the research before choosing laboratory materials.
Write one question before reading a product description: is the study about attention, anxiety symptoms, fatigue, or recovery after neurological injury? A change in a signaling marker is not the same as better concentration. A disease-specific trial is not a trial in healthy people trying to work more efficiently.
Semax is a peptide with a neurological research history. A 2018 report examined 110 people after ischemic stroke and assessed BDNF, motor performance, and a functional index. Those endpoints concern rehabilitation; they do not establish everyday focus enhancement in healthy adults. [1]
A 2008 clinical study compared Selank with medazepam in 62 patients with generalized anxiety disorder or neurasthenia. Its assessments included psychometric scales and a serum marker. This is a specific clinical comparison, not evidence that every researcher will experience calmer focus. [2]
Your research map, checklists, and source links—in one free PDF.